Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label Study of Bevacizumab (Avastin®) in Combination With Pemetrexed or Pemetrexed and Carboplatin as First-line Treatment of Patients With Advanced or Recurrent Non-squamous Non-small Cell Lung Cancer

NCT00976456 is registered in ClinicalTrials.gov with PD Dr. med. Wolfgang Schuette as lead sponsor.

NCT NCT00976456
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00976456 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label Study of Bevacizumab (Avastin®) in Combination With Pemetrexed or Pemetrexed and Carboplatin as First-line Treatment of Patients With Advanced or Recurrent Non-squamous Non-small Cell Lung Cancer
Lead sponsor
PD Dr. med. Wolfgang Schuette
Phase
Phase 3
Overall status
Completed
Start date
September 30, 2009
Completion date
October 31, 2014
Enrollment
271 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-squamous non-small cell lung cancer